Cleared Traditional

K170231 - iHealth Align Gluco-Monitoring System (BG1)

Also marketed or referenced as:
iHealth Wireless Smart Gluco-Monitoring System (BG5) 

K170231 is an FDA 510(k) clearance for iHealth Align Gluco-Monitoring System (BG1), manufactured by Andon Health Co, Ltd.. The device is a Class 2 Chemistry device with product code NBW cleared through the Traditional 510(k) pathway after a 233-day FDA review.

Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
Sep 2017
Decision
233d
Days
Class 2
Risk

K170231 is an FDA 510(k) clearance for the iHealth Align Gluco-Monitoring System (BG1). Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Andon Health Co, Ltd. (Tianjin, CN). The FDA issued a Cleared decision on September 15, 2017 after a review of 233 days - an extended review cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Andon Health Co, Ltd. devices

FDA 510(k) Submission Details - K170231

510(k) Number K170231 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 25, 2017
Decision Date September 15, 2017
Days to Decision 233 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
145d slower than avg
Panel avg: 88d · This submission: 233d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NBW Device Classification - Class 2, Special Controls

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 510
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K170231.
Gold AQ Blood Glucose Monitoring System
K170264 · Changsha Sinocare, Inc. · Oct 2017
FreeStyle Precision Neo Blood Glucose Test Strips
K171941 · Abbott Diabetes Care, Inc. · Sep 2017
NuvoMed Wireless Blood Glucose Monitoring System (Model BGM-6/0352)
K171822 · Biotest Medical Corporation · Sep 2017
WowGoHealth Blood Glucose Monitoring System
K171785 · Biotest Medical Corporation · Sep 2017
GLUCOCARD W Blood Glucose Monitoring System
K170064 · Arkray Factory, Inc. · Aug 2017
Dario Blood Glucose Monitoring System
K163159 · Labstyle Innovations, Ltd. · Jul 2017